Evidence map›Paper›PMID 34516292›Full record

ReviewAnnual review of pharmacology and toxicology2022

Synthetic Retinoids Beyond Cancer Therapy.

Lorraine J Gudas

Open access · bronzeAbstract readReview
In one paragraph

Review in Annual review of pharmacology and toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. A Retinoid Antagonist Attenuates Bone Growth Inhibition Caused by Growth Plate Injury in Mice.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Retinoic acid receptor α activity in proximal tubules prevents kidney injury and fibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  17. Review
  18. Vitamin A and retinoid signaling in the kidneys.Pharmacology & therapeutics · 2023
    Review
  19. Retinoid metabolism: new insights.Journal of molecular endocrinology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Lorraine J GudasDepartment of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA; email: ljgudas@med.cornell.edu.
Cornell University · US

Funding

Gene Nutrient Interactions in Kidney FunctionR01DK113088 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2018 to 2025
$3.7M
Uncovering the Role of Retinoic Acid Receptor Beta in Alcoholic Liver DiseasesR21AA027637 · NIAAA · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2019 to 2020
$445k
NIAAA NIH HHS R21 AA027637NIDDK NIH HHS R01 DK113088
6 · The paper itself

Abstract

While the uses of retinoids for cancer treatment continue to evolve, this review focuses on other therapeutic areas in which retinoids [retinol (vitamin A), all-

Indexed as

NeoplasmsRetinoidsEpigenesis, GeneticHumansReceptors, Retinoic AcidRetinoid X ReceptorsUnited StatesReceptors, Retinoic AcidRetinoidsRetinoid X Receptorschronic kidney diseasedifferentiationfibrosisnonalcoholic fatty liver diseasenuclear receptorstem cellstranscription

Identifiers

PMID34516292
PMCPMC10264058
OpenAlexW3199997891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.